Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Public authority · France
Declared costs: €25K+ a year · in the register since 2018
Industry association · Belgium
Declared costs: €100K+ a year · in the register since 2009
Medicinal products for human use · Standards of quality and safety for substances of human origin intended for human application
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
EuropaBio · filed 27 Apr 2021 · source
The evaluation and revision of the general pharmaceutical legislation is the opportunity to create a future-proof, patient-oriented and leading life sciences and biotechnology sector in the EU. New biotechnology-derived vaccines and treatments have helped to tackle numerous life-threatening illnesses. Targeted cell and gene therapies and new mRNA platforms are paving the way for future treatments.
Etablissement Français du Sang (French Blood Establishment) · filed 19 Sept 2023 · source
LEtablissement Français du Sang (EFS) thanked the European Commission for its proposal, which met some of the stakeholders’ expectations, but created uncertainty about cross-border products. In particular, we would like to welcome the following points: The reaffirmation of the principle of voluntary and unpaid donation left the harmonisation of the framework for ATMPs prepared under hospital exemption The…
Filed in French · English published by the European Commission
EuropaBio · filed 9 Oct 2023 · source
In the last 20 years, biotech transformed the pharmaceutical industry and enabled the development of breakthrough therapies that are live-saving or significantly improving quality of life of patients and their families. The development of biotech in Europe also continues to positively contribute to the regions economic well-being.
Etablissement Français du Sang (French Blood Establishment) · filed 14 Dec 2020 · source
EFS fully supports the comments provided by the French Ministry of Health. The additional comments presented aim to address in more detail specific issues we identified in our areas of expertise. EFS does not agree with the statement “the lack of […] national monitoring provisions for the supply of BTC makes it difficult to predict EU supply interruptions and to take action to mitigate the risks to patients” when it…
EuropaBio · filed 7 Sept 2022 · source
EuropaBio welcomes the adoption of the proposal for a Regulation on SoHO revising the EU’s Blood, Tissues, and Cells (BTC) legislation. The EU needs a predictable, future-proof, and robust SoHO framework to ensure the uptake of transformative advanced therapies which hold great potential for both the health and wellbeing of patients and the sustainability of healthcare systems.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.